CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock
September 09, 2016 09:15 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute...
CoLucid Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 08, 2016 16:01 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute...
CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine
September 06, 2016 07:00 ET
|
CoLucid Pharmaceuticals, Inc
100 mg and 200 mg doses of lasmiditan efficacious on headache pain freedom and most bothersome symptom free at the two-hour time point (p < 0.001)Lasmiditan was well tolerated with no significant...
CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights
August 10, 2016 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the quarter ended June 30, 2016. Corporate...
CoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting in New York City
June 22, 2016 16:01 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc., (Nasdaq:CLCD) a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...
CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine
June 07, 2016 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...
CoLucid Pharmaceuticals to Participate at the Jefferies 2016 Healthcare Conference
June 02, 2016 08:58 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...
CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine
May 19, 2016 12:46 ET
|
CoLucid Pharmaceuticals, Inc
First Patient Randomized in SPARTAN StudyTrial Being Conducted Under Special Protocol Assessment Agreement with FDA CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals,...
CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights
May 11, 2016 16:01 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the first quarter ended March 31, 2016. Corporate...
CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors
March 15, 2016 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., March 15, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...